MIT researchers show how flu viruses mutate

Researchers from the Massachusetts Institute of Technology (MIT) publish revelations about the mechanism behind antigenic drift, a feat that could help flu vaccine designers produce vaccines that do not induce the evolution of tougher viruses

Amy Swinderman
CAMBRIDGE, Mass.—While many people are lining up for theirseasonal flu shot, they may find that their immune system responds by enablingthe virus to mutate to a different—and even more infectious—form. The mechanismbehind this virus mutation, called antigenic drift, has now been revealed in astudy by researchers from the Massachusetts Institute of Technology (MIT).
 
 
The study, "Networks link antigenic andreceptor-bindingsites of influenza hemagglutinin: Mechanistic insight into fitter strainpropagation," was published Dec. 19 in the online edition of Scientific Reports, an open-accessjournal published by Nature. In it,the researchers observed a flu virus passing through pre-vaccinated mice andobserved that emergent antigenic site mutations on the viral protein hemagglutinin(HA) impacted host receptor-binding affinity—and therefore, the evolution offitter influenza strains.
 
 
Flu shots are reformulated every year as new flu strainsemerge, but vaccines can also stimulate production of antibodies that target asection of the HA protein called the antigenic site. In 2009, MIT researcherRam Sasisekharan and scientists at the National Institute of Allergy andInfectious Diseases (NIAID) reported that when a virus encounters suchantibodies, it can evolve into a slightly altered strain that can spread topeople who have not been vaccinated.
 
 
To further understand this phenomenon, Sasisekharan and hiscolleagues analyzed the network of amino acids that make up HA and identifiedwhich amino acids are most likely to undergo mutations that improve theviruses' ability to infect new hosts. The researchers then computed theSignificant Interactions Network (SIN) for each residue of HA and mapped the networksof antigenic site residues on the HA of influenza A virus subtype H1N1.
 
 
"Specific antigenic site residues are 'linked' to RBSresidues via their SIN and mutations within 'RBS-linked' antigenic residues cansignificantly influence receptor-binding affinity by impacting the SIN of keyRBS residues," the researchers concluded. "In contrast, other antigenic siteresidues do not have such 'RBS-links' and do not impact
receptor-binding affinity upon mutation."
 
 
According to Sasisekharan, the finding could help fluvaccine designers produce vaccines that do not induce the evolution of fitterviruses.
 
 
"This understanding of the relationship between theantigenic site and the receptor-binding site could be added to the currentmethods of vaccine selection and vaccine designs to limit drift," he told MIT'spress office. Sasisekharan is an Edward Hood Taplin Professor of HealthSciences and Technology and Biological Engineering at MIT, director of theHarvard-MIT Division of Health Sciences and Technology and senior author of thepaper. 
 
Continued analysis of circulating influenza HA sequences canpotentially accelerate and help in the design of ideal vaccines for each fluseason, according to MIT.
 
The study was supported by funding from the U.S. National Institutesof Health and the Singapore-MIT Alliance for Research and Technology.
  



Amy Swinderman

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue